Blood cancers

Transplant centres warned not to take frozen product quality for granted in COVID-19 era

Cryopreservation of allogeneic hematopoietic progenitor cell (HPC) products can lead to variable CD34+ cell recovery and viability, according to Australian research. The study, published in Blood Advances, says that cryopreservation of the products before recipients commence conditioning is now recommended by haematological societies including BMTSANZ and centres, to offset travel and other risks due to ...

Already a member?

Login to keep reading.

© 2021 the limbic